Skip to content

Advertisement

  • Meeting abstract
  • Open Access

Copper as diagnostic marker of cancers

  • 1,
  • 1,
  • 2,
  • 2,
  • 2,
  • 2,
  • 2,
  • 2,
  • 2,
  • 2,
  • 2,
  • 2,
  • 2,
  • 1,
  • 2 and
  • 1, 2
Hereditary Cancer in Clinical Practice201513 (Suppl 2) :A7

https://doi.org/10.1186/1897-4287-13-S2-A7

  • Published:

Keywords

  • Breast Cancer
  • Prostate Cancer
  • Breast Cancer Patient
  • Breast Cancer Risk
  • Inductively Couple Plasma Mass Spectrometry

The study was conducted to determine if serum copper level could be a useful marker for selection for control examinations and if serum copper level is a risk factor in developing cancer.

Copper was quantitatively measured in diluted serum samples by inductively coupled plasma mass spectrometry (ICP-MS) using mass spectrometer (Elan DRC-e, PerkinElmer) in standard mode. In our study, there were two independent groups of patients examined. In the first, retrospective model, there were patients diagnosed with prostate cancer (n = 166) and laryngeal cancer (n = 123) matched with healthy controls. This study showed that serum copper level above 1250 µg/l may be a useful marker for laryngeal examination, but is not a useful marker for prostate cancer early detection. In the second, prospective model, there were patents diagnosed with breast cancer (n = 42) matched with unaffected controls. Serum from breast cancer patients was collected 3 - 41 months before cancer diagnosis. This part of study showed that there is a tendency that breast cancer risk is about two times lower when copper serum level is in range between 1035 - 1311 µg/l. Further investigations are needed.

Authors’ Affiliations

(1)
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
(2)
Read - Gene, S.A., Grzepnica, Poland

Copyright

Advertisement